Drugs /

lutetium lu 177-neob

Back to Drugs List

Overview

NCI Definition [1]:
A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types

Clinical Trials

View Clinical Trials for lutetium lu 177-neob

Lutetium lu 177-neob has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating lutetium lu 177-neob, 1 is phase 1/phase 2 (1 open).

GRPR Overexpression is the most frequent biomarker inclusion criterion for lutetium lu 177-neob clinical trials.

Breast carcinoma, gastrointestinal stromal tumor, and glioblastoma are the most common diseases being investigated in lutetium lu 177-neob clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lutetium Lu 177-Neob
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lutetium lu 177-neob and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
lutetium 177-neob, [177lu]-neob, lutetium lu 177 dota-neobomb1, 177lu-neob
Drug Target(s) [2]:
GRPR
NCIT ID [1]:
C158734

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.